None listed
Conditions
Brief summary
The aim of this study is to ascertain whether a standard clinical dose of 320 mg or a 640 mg dose of a specific extract of Bacopa Monnieri [KeenMind (Registered Trademark) - CDRI 08] would acutely affect cognition, mood, anxiety and stress at an earlier timepoint than previous Bacopa Monnieri supplementation studies. This study will investigate the cognitive and stress effects of a two doses of bacopa compared to placebo. Participants will be required to consume one of three treatments on each testing day, and will consume the other treatments on the other two days of testing. There will be a seven day washout period and the process will be repeated again. (1) Bacopa – 320mg (2) Bacopa – 640mg (3) Placebo
Interventions
On each testing day, participants consume four capsules containing an inert placebo, 320mg of KeenMind(Registered Trademark) (CDRI 08) Bacopa Monnieri (BM) extract or 640mg of KeenMind (Registered Trademark) (CDRI 08) BM extract. KeenMind (Registered Trademark) (CDRI 08) is standardized for no less than 55% of total bacosides. Each capsule contains 160 mg BM extract (25:1) equivalent to 4 g of dried herb.
Each participant is required to attend a total of 4 sessions (1 practice visit and 3 stud
On each testing day, participants consume four capsules containing an inert placebo, 320mg of KeenMind(Registered Trademark) (CDRI 08) Bacopa Monnieri (BM) extract or 640mg of KeenMind (Registered Trademark) (CDRI 08) BM extract. KeenMind (Registered Trademark) (CDRI 08) is standardized for no less than 55% of total bacosides. Each capsule contains 160 mg BM extract (25:1) equivalent to 4 g of dried herb. Each participant is required to attend a total of 4 sessions (1 practice visit and 3 study visits) that will be conducted one week apart to ensure sufficient washout between each acute condition. Total amount of testing days is 4 weeks (inclusive of practice visit). There will be three separate testing days where either the placebo, 320 mg of KeenMind (Registered Trademark) or 640 mg of KeenMind (Registered Trademark) will be taken exclusively each day.
Sponsors
Swinburne University of Technology
Study design
Allocation
Randomised controlled trial
Intervention model
Crossover
Primary purpose
Treatment
Masking
Blinded (masking used)
Eligibility
Sex/Gender
All
Age
18 Years to 44 Years
Healthy volunteers
Yes
Inclusion criteria
- Non-smoker - Age between 18 and 44 years - Healthy (absence of all exclusion criteria) male and female adults - Not taking any medication, herbal extracts, vitamin supplements or illicit drugs - Not pregnant or lactating - Participants must abstain from caffeine-containing foods/beverages and alcohol for 24 hours prior to the training session and each testing session. - Written informed consent obtained
Exclusion criteria
- Smoker - History of psychiatric disorders or neurological diseases - Suffering from endocrine, gastrointestinal or bleeding disorders - Taking any medication, herbal extracts, vitamin supplements or illicit drugs - Pregnant or lactating
Outcome results
None listed